AOD 9604 (5mg)

Description

AOD 9604 (5mg) is a high-purity, research-grade synthetic peptide supplied as a lyophilized (freeze-dried) powder in a single sterile vial. This 5mg vial is intended exclusively for laboratory and scientific research purposes, not for human consumption, therapeutic use, or medical treatment. AOD 9604 is a modified fragment of human growth hormone (hGH), specifically the C-terminal sequence (amino acids 176-191) with an added N-terminal tyrosine for enhanced stability.

Key Specifications

• Molecular Formula: C₇₈H₁₂₃N₂₃O₂₃S₂
• Molecular Weight: 1815.1 g/mol (approximately 1815 Daltons)
• Amino Acid Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF), with a disulfide bridge between Cys residues
• CAS Number: 221231-10-3 (or related variants)
• Purity: Typically ≥98-99% (verified by HPLC and third-party COA in research-grade products)
• Appearance: White to off-white lyophilized powder
• Form: Single 5mg vial (requires reconstitution with bacteriostatic water or sterile solution for research applications)
• Storage: Store lyophilized at -20°C or colder; after reconstitution, refrigerate at 2-8°C and use promptly to maintain stability

Research Background and Mechanism

AOD 9604 was originally developed in the 1990s as an “Anti-Obesity Drug” (hence AOD) by mimicking the lipolytic (fat-breaking) properties of natural hGH without triggering broader growth-promoting effects, such as elevated IGF-1 levels, insulin resistance, or impacts on glucose homeostasis. Preclinical and early clinical studies (including Phase II trials) explored its potential to:

• Stimulate lipolysis (breakdown of stored fat)
• Inhibit lipogenesis (formation of new fat)
• Enhance fat metabolism and oxidation, particularly in adipose tissue
• Support metabolic regulation without significant appetite suppression or systemic hormonal disruption

Animal models (e.g., obese rats and mice) demonstrated weight reduction and fat loss effects, while human trials showed good tolerability with minimal adverse events reported across hundreds of participants.

Potential Research Applications

In laboratory settings, AOD 9604 is investigated for:

• Mechanisms of targeted fat metabolism and energy expenditure
• Adipose tissue regulation and lipid pathways
• Potential supportive roles in metabolic studies, joint/cartilage research (e.g., osteoarthritis models), or hypercholesterolemia models
• Comparisons to full hGH or other lipolytic agents

It does not stimulate IGF-1 production or affect growth pathways like full-length hGH.

Important Notes

AOD 9604 is not approved by major regulatory bodies (e.g., FDA, EMA) for human use, weight loss, or any medical condition. Development as a therapeutic was discontinued after mixed efficacy results in later trials. All products labeled as AOD 9604 are sold strictly for research and in vitro/in vivo experimentation by qualified professionals.

For research use only. Not for human or veterinary consumption. Always handle peptides with proper lab protocols, including reconstitution, sterile techniques, and adherence to safety guidelines. Consult lab COAs and conduct independent verification for purity and identity.